Has brigatinib/brigatinib been reimbursed by medical insurance?

Brigatinib/Brigatinib (Brigatinib), as a first-line treatment for ALK-positive non-small cell lung cancer, has completed marketing approval in China and has been included in the Category B scope of the National Medical Insurance List. This policy adjustment is of great significance to the majority of patients. In the past, targeted drugs were expensive and placed a heavy medication burden on patients. Medical insurance coverage allows more patients to obtain long-term treatment opportunities at a relatively reasonable cost.

Currently, brigatinib is available in various specifications on the market, including30mg 14 tablets, 90mg 7 tablets, 90mg 28 tablets and 180mg 7 tablets in different packages to meet the medication needs of different patients. The proportion and threshold of medical insurance reimbursement vary from region to region, and patients need to consult the local medical insurance department or hospital pharmacy for specific conditions. After entering the medical insurance, the actual out-of-pocket amount of brigatinib dropped significantly, which not only reduced the financial pressure on the family, but also improved treatment compliance.

From the perspective of medical insurance access, the coverage of brigatinib is mainly targeted atpatients with ALK-positive, locally advanced or metastatic non-small cell lung cancer. Its inclusion in the medical insurance catalog means that the government and medical system recognize its clinical value. Targeted drugs can accurately act on driver gene mutations at the molecular level and are more targeted and tolerable than traditional chemotherapy. Therefore, the support of medical insurance policies is actually promoting the upgrade of tumor treatment models.

It should be noted that although brigatinib is included in the medical insurance catalog, it is still a Class B drug, which means that there are certain restrictions on the reimbursement ratio and conditions, and the scope and ratio of medical insurance reimbursement will vary in different regions. Before taking medication, patients should consult their doctor and medical insurance policy interpretation in detail in order to plan a reasonable treatment plan. Overall, brigatinib's medical insurance access has brought new hope to domestic patients with ALK-positive lung cancer, making innovative drugs no longer out of reach.

Reference materials:https://www.alunbrig.com/